FACIO-SCAPULO-HUMERAL DYSTROPHY
Clinical trials for FACIO-SCAPULO-HUMERAL DYSTROPHY explained in plain language.
Never miss a new study
Get alerted when new FACIO-SCAPULO-HUMERAL DYSTROPHY trials appear
Sign up with your email to follow new studies for FACIO-SCAPULO-HUMERAL DYSTROPHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare muscle disease: experimental drug enters human trials
Disease control Recruiting nowThis study tests an experimental drug called ARO-DUX4 in 60 adults and teens with facioscapulohumeral muscular dystrophy type 1 (FSHD1), a genetic condition that causes muscle weakness. The main goal is to check the drug's safety and how it moves through the body. Participants re…
Matched conditions: FACIO-SCAPULO-HUMERAL DYSTROPHY
Phase: PHASE1, PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New drug trial hopes to slow muscle loss in FSHD
Disease control Recruiting nowThis study tests an experimental drug called AOC 1020 in 200 adults with facioscapulohumeral muscular dystrophy (FSHD), a genetic disease that causes progressive muscle weakness. Participants receive either the drug or a placebo by IV every few weeks. The goal is to see if the dr…
Matched conditions: FACIO-SCAPULO-HUMERAL DYSTROPHY
Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated May 11, 2026 20:46 UTC